The document discusses various types of viral hepatitis caused by hepatotropic viruses such as HAV, HBV, HCV, HDV, and HEV, detailing transmission routes, clinical manifestations, and prevention methods. It highlights the similarities in symptoms across different hepatitis viruses, with HAV and HEV primarily transmitted enterically and HBV transmitted parenterally. Prevention measures include good hygiene, vaccination, and screening protocols to reduce the spread of these infections.

2.  Viral hepatitis is a systemic disease primarily
involving the liver.
Hepatotropic viruses : liver is the target organ and
the main site of virus replication
• Hepatitis A virus (HAV)
• hepatitis B virus (HBV)
• Hepatitis C virus (HCV)
• Hepatitis D virus (HDV, delta virus)
• Hepatitis E virus (HEV).

3.  Other viruses also infect other sites of the body, and
therefore are not exclusively hepatitis viruses.
• Yellow fever virus.
• Epstein-barr virus.
• Cytomegalovirus.

4.  The clinical manifestations of hepatitis are the same,
regardless of which virus is the cause.
is characterized by: Fever+ gastrointestinal symptoms
( anorexia, nausea, vomiting) +
Jaundice No jaundice
↓ ↓
icteric hepatitis anicteric hepatitis
(is more common).

5. Hepatotropic viruses
Transmitted enterically Transmitted parenterally
-Intravenous route
virus is transmitted by contaminated food Intramuscular route
and water: Subcutaneous route
Intradermal route
HAV and HEV
HCV, HBV and HDV

6. Enterically transmitted hepatitis
viruses
Hepatitis A virus
Classification
• Family: Picornaviridae
• Genus: hepatovirus
• Only one serotype is known

7. Properties
• Icosahedral nucleocapsid.
• Nonenveloped.
• Genome: a single stranded RNA.
• The virus is stable to treatment with ether, acid and heat
(60°C for 1 hour).
• It can be destroyed by autoclaving) to sterilize)boiling for
5 min, or by chlorine.

8. Hepatitis A Virus

9. Transmission and epidemiology
HAV is transmitted by the fecal-oral route.
• Under crowded conditions and poor sanitation,
infection occurs at an early age, most children
become immune by age 10.
• With higher levels of poor sanitation, infection
occurs in older persons.

10. Clinical findings
 IP: 3-4 weeks
 Clinical illness:
• Asymptomatic infection is common in infants and
children.
• Disease is more severe in adults. (is symptomatic
infection)
 Outcome of infection:
Almost all cases (99%) recover completely in 2-4
weeks with life long immunity( no repeat infection)
There is no chronicity.

11. Pathogenesis
• Following ingestion, HAV enters the bloodstream
through the epithelium of the oropharynx or
intestine.
• The blood carries the virus to its target, the liver,
where it multiplies within hepatocytes and
Kupffer cells (liver macrophages).
• Virions are secreted into the bile and released in
stool.
• HAV is excreted in large quantities approximately
15 days prior to appearance of symptoms or anti-
HAV IgM antibodies in the blood

12. Hepatitis A Infection
Typical Serological Course
Symptoms Total anti-
HAV
Titre ALT
Fecal
HAV
IgM anti-HAV
0 1 2 3 4 5 6 1 2
2 4
Months after exposure

13. Laboratory diagnosis
 Detection of HAV antibodies:
• Anti-HAV IgM → acute hepatitis A
• Anti-HAV IgG → past infection or vaccination.
• ELISA is the method of choice for detecting these
antibodies.
 Detection of HAV antigen:
In stools by ELISA.
 Detection of HAV RNA:
In stools by PCR and nucleic acid hybridization.

14. Prevention and control
 Prevention of fecal contamination of food and
water.
 Good hygiene-hand washing.
 Chlorination of water

15. Active immunization
 A formalin inactivated HAV vaccine IS AVAILABLE
• Safe and effective
• Recommended for use in persons over 1 year of age.
• Two doses should be given: an initial dose , booster dose
6-12 months later.
Passive immunization
 Immune (gamma) globulin confers passive protection
when given 1-2 weeks after exposure to hepatitis A.
Immune globulin does not prevent the infection but makes
it mild or subclinical.

16. Hepatitis E virus
Properties
 The virus is a small.
 Non enveloped.
 Single stranded RNA virus.

17. Transmission
 HEV is transmitted enterically.
Clinical findings
 IP: ~ 40 days
 The disease resembles hepatitis A.
 WITH EXCEPTION of A high mortality rate in pregnant
women (fulminant hepatitis).
 Chronic liver disease does not occur.

18. Diagnosis
Detection of:
 Anti-HEV antibodies.
 HEV-RNA in serum.
Prevention and control
 General measures as with hepatitis A.
 There is no vaccine.

19. Parenterally-transmitted hepatitis
viruses
Hepatitis B virus
Properties
 Member of the hepadnavirus family.
 42 nm enveloped virion.
 Icosahedral nucleocapsid containing a partially
double-stranded circular DNA genome.

20. Electron microscopy of a patient s serum
reveals three different types of particles
These two forms are made
up exclusively of surface
antigen *
The virus is one of the smallest enveloped animal viruses, but
pleomorphic forms exist

21. Hepatitis B Virus

22. Pathogenesis
• Although replication takes place in the
liver, the virus spreads to the blood where
viral proteins and antibodies against them
are found in infected people.

23. Epidemiology and Transmission
 HBV is worldwide in distribution. Egypt lies within
the zone of moderate prevalence of chronic carriers
(2-7% of the population is HBsAg positive).
 High titers of the virus: blood and serum.
 Moderate levels: semen, saliva and vaginal secretion.

24. Geographic Distribution of Chronic HBV
Infection
HBsAg Prevalence
≥8% - High
2-7% - Intermediate
<2% - Low

25. Three main modes of transmission.
1-Percutaneous and permucosal exposure
to blood.
2- Sexual transmission.
3- Perinatal transmission.

26. 1-Percutaneous and permucosal exposure to blood.
 Transfusion of blood and blood products.
 Sharing of contaminated needles and syringes.
 The use of improperly sterilized instruments (even
in tattooing and ear piercing).
 Sharing of razors and tooth brushes.
2- Sexual transmission.
3- Perinatal transmission from mother to newborn.
 During birth or breast feeding.
 In-utero transmission is rare.

27. Clinical features
 The mean incubation period is 10-12 weeks.
 Many HBV infections are asymptomatic. Symptoms are
similar to that of hepatitis A, but tend to be more severe.
Outcome of infection
Adults Infants and young children
↓ ↓
90-95% recover completely. 80-95% chronic carriers.

28. Spectrum of chronic hepatitis B diseases
 Most chronic carriers are asymptomatic.
 Some develop chronic hepatitis → cirrhosis, liver failure
and death.
 Chronic carriers are at high risk of developing
hepatocellular carcinoma, especially those infected as
infants.
 HBV vaccine is the first vaccine to prevent a human
cancer.

29. Virologic and serologic events
following exposure to HBV

30. Acute Hepatitis B Virus Infection with Recovery
Typical Serologic Course
Symptoms
HBeAg anti-HBe
Total anti-HBc
Titer
HBsAg IgM anti-HBc anti-HBs
0 4 8 12 16 20 24 28 32 36 52 100
Weeks after Exposure

31. Progression to Chronic Hepatitis B Virus Infection
Typical Serologic Course
Acute Chronic
(6 months) (Years)
HBeAg anti-HBe
HBsAg
Total anti-
HBc
Titer
IgM anti-HBc
0 4 8 12 16 20 24 28 32 36 52 Years
Weeks after Exposure

32. Laboratory diagnosis
 HBV antigen and antibodies are usually
detected in serum by ELISA.
 HBV DNA is detected by PCR.

33. Interpretation of results
 Serologic tests can identify four stages of HBV infection.
Test Acute Window Complete Chronic
disease phase recovery carrier
state
HBsAg Positive Negative Negative Positive
Anti-HBs Negative Negative Positive Negative
Anti-HBc Positive Positive Positive Positive

34.  Persons immunized with HBV vaccine have anti-HBs but
not anti-HBc because the vaccine is purified HBsAg.
 The presence of HBeAg → high probability of
transmissibility.
The presence of anti-HBe → lower probability, but
transmission can still occur.
 The detection of viral DNA in the serum is strong
evidence that infectious virions are present.

35. Prevention and control
I-Hepatitis B vaccination is the most effective measure
to prevent HBV and its consequences.
1 .Plasma derived vaccine:
Purified HBsAg from healthy HBsAg positive carriers.
2. Recombinant DNA derived vaccine:
HBsAg produced in yeast cells by recombinant DNA
techniques.

36. The vaccine is recommended for:
1. All infants as part of their regular immunization
schedule.
2. Heath care personnel frequently exposed to blood or
blood products.
3. Patients receiving multiple transfusions or dialysis.
The vaccine is given in a three-dose regimen
0, 1, 6 months.

37. II-Hepatitis B immune globulin (HBIG) is used to
provide immediate, passive protection if it is given
soon after exposure.
Both the vaccine and HBIG should be administered
simultaneously (at different sites) to:
 Persons exposed to HBV percutaneously or by
contamination of mucosal surfaces.
 Infants born to HBV-positive mothers.
Both immediate and long term protection are
provided.

38. III-General measures
1. All blood for transfusion should be screened for HBV.
2. Proper sterilization of endoscopes and surgical instruments.
3. Only disposable needles and syringes should be used.
4. Standard precautions to prevent percutaneous injuries or
contact of non intact skin or mucous membrane with blood or
body fluids:
 Gloves should be worn when handling potentially
infectious material.
 Proper handling and disposal of sharps.
 Decontamination of spillage accidents with chlorine.